
Hidradenitis Suppurativa - Pipeline Insight, 2024
Description
Hidradenitis Suppurativa - Pipeline Insight, 2024
DelveInsight’s, “Hidradenitis Suppurativa - Pipeline Insight, 2024,” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hidradenitis Suppurativa: Overview
Hidradenitis suppurativa (HS), also called acne inversus, is a chronic inflammatory skin condition with lesions including deep-seated nodules and abscesses, draining tracts, and fibrotic scars. These lesions most commonly occur in intertriginous areas and areas rich in apocrine glands. Among the most common are axillary, groin, perianal, perineal, and inframammary locations. This activity reviews the cause, presentation and complications of Hidradenitis suppurativa and highlights the role of the interprofessional team in its management. The pathologic process of HS begins when a defective hair follicle becomes occluded and ruptures, spilling its contents, including keratin and bacteria, into the surrounding dermis. A chemotactic inflammatory response by surrounding neutrophils and lymphocytes can lead to abscess formation and subsequent destruction of the pilosebaceous unit and other adjacent structures. Prognosis is variable. There is no cure for this condition. The prognosis worsens if there is a delay in diagnosis and treatment during the early stages of the disease, and also if comorbid conditions of smoking and obesity (if present) are not addressed and improved.
""Hidradenitis Suppurativa - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hidradenitis Suppurativa pipeline landscape is provided which includes the disease overview and Hidradenitis Suppurativa treatment guidelines. The assessment part of the report embraces, in depth Hidradenitis Suppurativa commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence in Hidradenitis Suppurativa R&D. The therapies under development are focused on novel approaches to treat/improve in Hidradenitis Suppurativa.
- In April 2022, Ascentage Pharma announced that the combination of palbociclib and APG-2449 synergistically inhibits tumor growth in mesothelioma and such effect is mediated by induced autophagy and enhanced cellular senescence. The preclinical study suggests that APG-2449 combined with CDK4/6 inhibitors may have therapeutic potential in mesothelioma and may warrant future clinical development.
- In April 2022, AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The Company’s proprietary anti-inflammatory pipeline includes imsidolimab, its anti-IL-36R antibody, previously referred to as ANB019, for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, and moderate-to-severe hidradenitis suppurativa; Imsidolimab top-line data from the HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in the third quarter of 2022.
- In February 2022, InflaRx, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced the presentation of new data with vilobelimab (IFX-1), a first-in-class anti-C5a antibody, demonstrating significantly elevated baseline C5a levels in moderate and severe Hurley Stage II and III hidradenitis suppurativa (HS) patients compared to healthy volunteers.
Hidradenitis Suppurativa Emerging Drugs
- Vilobelimab: InflaRx
- Secukinumab: Novartis
- Avacopan: ChemoCentryx
- Imsidolimab: AnaptysBio
- Spesolimab: Boehringer Ingelheim
Further product details are provided in the report……..
Hidradenitis Suppurativa: Therapeutic Assessment
This segment of the report provides insights about the different Hidradenitis Suppurativa drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hidradenitis Suppurativa
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Hidradenitis Suppurativa: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hidradenitis Suppurativa therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hidradenitis Suppurativa drugs.
Hidradenitis Suppurativa Report Insights
- Hidradenitis Suppurativa Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hidradenitis Suppurativa drugs?
- How many Hidradenitis Suppurativa drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hidradenitis Suppurativa?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hidradenitis Suppurativa?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hidradenitis Suppurativa and their status?
- What are the key designations that have been granted to the emerging drugs?
- InflaRx
- Novartis
- UCB
- ChemoCentryx
- Eli Lilly and Company
- Janssen Biotech
- AbbVie
- Pfizer
- Amgen
- Incyte Corporation
- CSL Behring
- Kymera Therapeutics
- Lytix Biopharma
- Aclaris Therapeutics
- Boehringer Ingelheim
- Azora Therapeutics
- Vilobelimab
- Secukinumab
- Bimekizumab
- Avacopan
- LY3041658
- Bermekimab
- Guselkumab
- Risankizumab
- PF 6650833
- Apremilast
- INCB54707
- CSL324
- IRAK4
- LTX-109
- ATI-450
- Spesolimab
- AT193
Table of Contents
115 Pages
- Introduction
- Executive Summary
- Hidradenitis Suppurativa : Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Hidradenitis Suppurativa – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Vilobelimab: InflaRx
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Spesolimab: Boehringer Ingelheim
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- AT193: Azora Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Hidradenitis Suppurativa Key Companies
- Hidradenitis Suppurativa Key Products
- Hidradenitis Suppurativa - Unmet Needs
- Hidradenitis Suppurativa - Market Drivers and Barriers
- Hidradenitis Suppurativa - Future Perspectives and Conclusion
- Hidradenitis Suppurativa Analyst Views
- Hidradenitis Suppurativa Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.